New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - roxithromycin 300mg;   - coated tablet - 300 mg - active: roxithromycin 300mg   excipient: colloidal silicon dioxide glucose hyprolose hypromellose magnesium stearate maize starch povidone propylene glycol purified talc titanium dioxide water

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - topiramate 100mg;   - film coated tablet - 100 mg - active: topiramate 100mg   excipient: colloidal silicon dioxide croscarmellose sodium opadry yellow 85g32313 magnesium stearate mannitol microcrystalline cellulose pregelatinised maize starch - topiramate actavis is indicated in adults and children. topiramate actavis tablet range is not suitable for any children weighing less than 25 kg and is not suitable as monotherapy for children or adolescents weighing less than 50 kg. - as monotherapy in patients with newly diagnosed epilepsy - for conversion to monotherapy in patients with epilepsy - as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - topiramate 200mg;   - film coated tablet - 200 mg - active: topiramate 200mg   excipient: colloidal silicon dioxide croscarmellose sodium opadry ii pink 85g34776 magnesium stearate mannitol microcrystalline cellulose pregelatinised maize starch - topiramate actavis is indicated in adults and children. topiramate actavis tablet range is not suitable for any children weighing less than 25 kg and is not suitable as monotherapy for children or adolescents weighing less than 50 kg. - as monotherapy in patients with newly diagnosed epilepsy - for conversion to monotherapy in patients with epilepsy - as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - topiramate 25mg;   - film coated tablet - 25 mg - active: topiramate 25mg   excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose opadry white 85f18422 pregelatinised maize starch - topiramate actavis is indicated in adults and children. topiramate actavis tablet range is not suitable for any children weighing less than 25 kg and is not suitable as monotherapy for children or adolescents weighing less than 50 kg. - as monotherapy in patients with newly diagnosed epilepsy - for conversion to monotherapy in patients with epilepsy - as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - topiramate 50mg;   - film coated tablet - 50 mg - active: topiramate 50mg   excipient: colloidal silicon dioxide croscarmellose sodium opadry yellow 85g32312 magnesium stearate mannitol microcrystalline cellulose pregelatinised maize starch - topiramate actavis is indicated in adults and children. topiramate actavis tablet range is not suitable for any children weighing less than 25 kg and is not suitable as monotherapy for children or adolescents weighing less than 50 kg. - as monotherapy in patients with newly diagnosed epilepsy - for conversion to monotherapy in patients with epilepsy - as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - venlafaxine hydrochloride 169.72mg equivalent to venlafaxine 150 mg;  ;  ;   - modified release tablet - 150 mg - active: venlafaxine hydrochloride 169.72mg equivalent to venlafaxine 150 mg       excipient: cellulose acetate colloidal silicon dioxide cellulose acetate 398-10 nf macrogol 400   magnesium stearate mannitol microcrystalline cellulose opadry white y-30-18037 povidone - · arrow – venlafaxine xr is indicated for the treatment of major depression. arrow – venlafaxine xr is also indicated for the prevention of relapse and recurrence of major depression where appropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - venlafaxine hydrochloride 254.58mg equivalent to venlafaxine 225 mg;  ;  ;   - modified release tablet - 225 mg - active: venlafaxine hydrochloride 254.58mg equivalent to venlafaxine 225 mg       excipient: cellulose acetate colloidal silicon dioxide cellulose acetate 398-10 nf macrogol 400   magnesium stearate mannitol microcrystalline cellulose opadry white y-30-18037 povidone - · arrow – venlafaxine xr is indicated for the treatment of major depression. arrow – venlafaxine xr is also indicated for the prevention of relapse and recurrence of major depression where appropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - venlafaxine hydrochloride 42.43mg equivalent to venlafaxine 37.5 mg;  ;  ;   - modified release tablet - 37.5 mg - active: venlafaxine hydrochloride 42.43mg equivalent to venlafaxine 37.5 mg       excipient: cellulose acetate colloidal silicon dioxide cellulose acetate 398-10 nf macrogol 400   magnesium stearate mannitol microcrystalline cellulose opadry white y-30-18037 povidone - · arrow – venlafaxine xr is indicated for the treatment of major depression. arrow – venlafaxine xr is also indicated for the prevention of relapse and recurrence of major depression where appropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - venlafaxine hydrochloride 84.86mg equivalent to venlafaxine 75 mg;  ;  ;   - modified release tablet - 75 mg - active: venlafaxine hydrochloride 84.86mg equivalent to venlafaxine 75 mg       excipient: cellulose acetate colloidal silicon dioxide cellulose acetate 398-10 nf macrogol 400   magnesium stearate mannitol microcrystalline cellulose opadry white y-30-18037 povidone - · arrow – venlafaxine xr is indicated for the treatment of major depression. arrow – venlafaxine xr is also indicated for the prevention of relapse and recurrence of major depression where appropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - morphine sulfate pentahydrate 100mg - modified release tablet - 100 mg - active: morphine sulfate pentahydrate 100mg excipient: hyetellose hypromellose magnesium stearate opadry grey oy-8238 povidone purified talc - arrow-morphine la tablets are indicated for the prolonged relief of opioid responsive severe and intractable pain in adults. use in non-malignant pain: the use of arrow-morphine la tablets for the treatment of pain which is not due to malignancy should be restricted to situations where: · all other conservative methods of analgesia have been tried and have failed; · the pain is having a significant impact on the patient's quality of life; · there is no psychological contraindication, drug seeking behaviour or history of drug abuse.